SCHEMBL621864

SCHEMBL621864

CCCCCCCCCCCCCCCC(F)C(F)(F)C(F)(F)I

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.39
LMNA P02545 1/20 0.35
DNM1 Q05193 2/20 0.34
CA2 P00918 1/20 0.34
OPRM1 P35372 1/20 0.33
TSHR P16473 1/20 0.33
THRB P10828 1/20 0.33
FAAH O00519 4/20 0.32
CES1 P23141 3/20 0.32
FDPS P14324 2/20 0.32
GPR84 Q9NQS5 2/20 0.32
CES2 O00748 1/20 0.32
MEN1 O00255 1/20 0.32
CYP1A2 P05177 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29150221 0.91 DNM1 (0.32) DNM1
SCHEMBL45230 0.83 MAPT (0.42) MAPTLMNADNM1OPRM1TSHR
SCHEMBL27552948 0.83 MAPT (0.42) MAPTLMNADNM1OPRM1TSHR
SCHEMBL45436 0.80 MAPT (0.39) MAPTLMNADNM1OPRM1TSHR
SCHEMBL23825142 0.79 MAPT (0.44) MAPTLMNACA2FAAHCES1
SCHEMBL23824979 0.79 MAPT (0.44) MAPTLMNAFAAHCES1FDPS
SCHEMBL23825196 0.79 MAPT (0.44) MAPTLMNAFAAHCES1FDPS
SCHEMBL31316959 0.79 MAPT (0.39) MAPTLMNADNM1OPRM1TSHR
SCHEMBL23825039 0.79 MAPT (0.44) MAPTLMNACA2FAAHCES1
SCHEMBL23825006 0.79 MAPT (0.44) MAPTLMNAFAAHCES1FDPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100254904-A1 Novel therapeutic delivery systems BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC. 2010-10-07 US claimed
US-6479034-B1 Method of preparing gas and gaseous precursor-filled microspheres BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC. 2002-11-12 US claimed
US-20020159952-A1 Novel acoustically active drug delivery systems BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC. 2002-10-31 US claimed
US-6443898-B1 Therapeutic delivery systems IMARX PHARMACEUTICAL CORP. 2002-09-03 US claimed
EP-0981333-A4 NOVEL ACOUSTICALLY ACTIVE DRUG DELIVERY SYSTEMS IMARX PHARMACEUTICAL CORP (US) 2002-04-24 EP claimed
US-6071495-A TEMPERATURE ACTIVATED; PARTICULARLY USEFUL, FOR EXAMPLE, IN ULTRASONIC IMAGING APPLICATIONS AND IN THERAPEUTIC DRUG DELIVERY SYSTEMS. IMARX PHARMACEUTICAL CORP. (US) 2000-06-06 US claimed
EP-0981333-A1 NOVEL ACOUSTICALLY ACTIVE DRUG DELIVERY SYSTEMS IMARX PHARMACEUTICAL CORP. (US) 2000-03-01 EP claimed
US-5853752-A Methods of preparing gas and gaseous precursor-filled microspheres IMARX PHARMACEUTICAL CORP. (US) 1998-12-29 US claimed
WO-1998051284-A1 NOVEL ACOUSTICALLY ACTIVE DRUG DELIVERY SYSTEMS IMARX PHARMACEUTICAL CORP. (US) 1998-11-19 WO claimed
EP-0802788-A4 NOVEL THERAPEUTIC DELIVERY SYSTEMS UNGER EVAN C (US) 1998-09-09 EP claimed
EP-0712293-A4 METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES UNGER EVAN C (US) 1998-05-06 EP claimed
EP-0802788-A1 NOVEL THERAPEUTIC DELIVERY SYSTEMS UNGER, Evan C (US) 1997-10-29 EP claimed
US-5585112-A TEMPERATURE-ACTIVATED FLUORINE-CONTAINING GAS; USEFUL IN ULTRASONIC IMAGING AND DRUG DELIVERY SYSTEMS; FDA ORANGE BOOK LISTED PATENT FOR PERFLUTREN IMARX PHARMACEUTICAL CORP. (US) 1996-12-17 US claimed
EP-0712293-A1 METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES UNGER, Evan C (US) 1996-05-22 EP claimed
WO-1994028780-A2 METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES UNGER EVAN C (US) 1994-12-22 WO claimed
WO-1994028874-A1 NOVEL THERAPEUTIC DELIVERY SYSTEMS UNGER EVAN C (US) 1994-12-22 WO claimed
EP-2514387-B1 ULTRASONIC DRUG DELIVERY SYSTEM FOR DENTAL USE NAT CT GERIATRICS & GERONTOLOGY (JP) 2018-03-21 EP disclosed
US-9452036-B2 Dental ultrasonic drug delivery system and dental ultrasonic drug delivery method NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) 2016-09-27 US disclosed
WO-1994028780-A2 METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES UNGER EVAN C (US) 1994-12-22 WO disclosed
WO-1994028874-A1 NOVEL THERAPEUTIC DELIVERY SYSTEMS UNGER EVAN C (US) 1994-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020159952-A1 Novel acoustically active drug delivery systems AURKA, AURKC, MTDH MAPT 648/4885LMNA 1467/4885DNM1 1327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.